Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice
What this study shows
Female 129/Sv inbred mice received rapamycin intermittently, 2 weeks in every month, from 2 months of age for the rest of their lives. Treated mice gained less weight with age, showed a slower estimated rate of ageing, lived longer, with the gain most visible among the last survivors, and developed spontaneous tumours later. 22.9% of rapamycin-treated mice were still alive when the last control mouse died. The paper provided evidence that an intermittent rapamycin schedule can extend lifespan in a normal inbred mouse strain, adding to earlier results in genetically heterogeneous mice. Boundary: Female mice of a single inbred strain (129/Sv) only; drafted from the abstract only, so dose, group sizes and median-lifespan statistics are not given here.
At a glance
| Evidence type | A Animal model Marked A because it is an animal intervention or observation study measuring an organismal outcome (model: Female 129/Sv inbred mice given rapamycin intermittently (2 weeks per month) from 2 months of age for life; survival, body weight, ageing-rate measures and spontaneous tumours); the code names the system studied -- animal work can be rigorous and still not be human data. |
| Study type | 4 - Animal Study |
| Model system | Female 129/Sv inbred mice given rapamycin intermittently (2 weeks per month) from 2 months of age for life; survival, body weight, ageing-rate measures and spontaneous tumours |
| Journal | Cell Cycle |
| Year | 2011 |
| Peer reviewed | Yes |
| Record last updated | 2026-10-01 |
| Source | DOI 10.4161/cc.10.24.18486 · PMID 22107964 |
Extracted findings
These fields were extracted from the paper with AI assistance and have not been checked against the source. Read them as a pointer into the paper, not as curated claims; where they disagree with the curated summary above, the curated summary stands.
| Intervention | Rapamycin, intermittent (2 weeks per month), lifelong from 2 months of age |
| Target | mTOR (TOR) |
| Model | Mouse (female 129/Sv) |
| Effect | Increased lifespan, reduced age-related weight gain, delayed spontaneous cancer |
In the Atlas
Related topics
Links in the pathway map
- Supports Rapamycin activates Longevity
More studies on this topic
- Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling (2008)
- Synergistic role of TFEB/TFE3 and mTORC1 in kidney cystogenesis and tumorigenesis (2026)
- Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E (2010)
- The translational landscape of mTOR signalling steers cancer initiation and metastasis (2012)
Thank you. Your answer was counted anonymously.